Transdermal Rotigotine User Surveillance Study (TRUST)
A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease
Sponsor: UCB Pharma
Listed as NCT00599339, this observational or N/A phase trial focuses on Idiopathic Parkinson Disease and remains completed. Sponsored by UCB Pharma, it has been updated 9 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)All patients attending the physician and fulfilling the eligibility criteria are included.
All patients attending the physician and fulfilling the eligibility criteria are included.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2018 — Jan 2021 [monthly]
Completed
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aalen, Germany , Aarhus, Denmark , Achim, Germany , Acquaviva delle Fonti, Italy , Aguascalientes, Mexico , Alexandroupoli, Greece , Alzenau in Unterfranken, Germany , Alzira (Valencia), Spain , Ancona, Italy and 143 more locations